1. Search Result
Search Result
Results for "

Hrd1

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

2

Natural
Products

3

Isotope-Labeled Compounds

1

Antibodies

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0124
    Zonisamide
    3 Publications Verification

    AD 810; CI 912

    Carbonic Anhydrase Apoptosis Neurological Disease
    Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy [1] .
    Zonisamide
  • HY-W018161
    Hexadecanedioic acid
    1 Publications Verification

    Thapsic acid

    IRE1 Ferroptosis Keap1-Nrf2 Glutathione Peroxidase Metabolic Disease
    Hexadecanedioic acid (Thapsic acid) is an orally active metabolite produced by B. uniformis. Hexadecanedioic acid inhibits IRE1α-XBP1s-mediated flipogenesis and ferroptosis. Hexadecanedioic acid downregulates XBP1 and Hrd1 expression, activates the Nrf2/SLC7A11/GPX4 pathway. Hexadecanedioic acid can be used for the research of metabolic-associated fatty liver disease [1].
    Hexadecanedioic acid
  • HY-49116

    E1/E2/E3 Enzyme Infection Inflammation/Immunology
    CP26 is a small molecule inhibitor of protein dislocation from the ER lumen to the cytosol. CP26 targets the Hrd1 complex, inhibits ERAD, and induces ER stress [1].
    CP26
  • HY-160700

    Deubiquitinase JNK Cancer
    TNG348 is an orally available allosteric inhibitor of the ubiquitin-specific protease USP1. TNG348 specifically and efficiently inhibits the activity of USP1, inhibiting its deubiquitination of proliferative PCNA and FANCD2, thereby disrupting the DNA repair process. TNG348 has inhibitory activity against breast and ovarian cancers carrying BRCA1/2 mutations and other homologous recombination defects (HRD) .
    TNG348
  • HY-B0124A

    AD 810 sodium; CI 912 sodium

    Carbonic Anhydrase Apoptosis Cardiovascular Disease Neurological Disease
    Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy [1] .
    Zonisamide sodium
  • HY-B0124R

    AD 810 (Standard); CI 912 (Standard)

    Reference Standards Carbonic Anhydrase Apoptosis Neurological Disease
    Zonisamide (Standard) is the analytical standard of Zonisamide. This product is intended for research and analytical applications. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy [1] .
    Zonisamide (Standard)
  • HY-B0124S2

    AD 810-13C6; CI 912-13C6

    Isotope-Labeled Compounds Carbonic Anhydrase Apoptosis Neurological Disease
    Zonisamide- 13C6 (AD 810- 13C6) is 13C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy [1] .
    Zonisamide-13C6
  • HY-W018161R

    Thapsic acid (Standard)

    Reference Standards IRE1 Ferroptosis Keap1-Nrf2 Glutathione Peroxidase Metabolic Disease
    Hexadecanedioic acid (Thapsic acid) (Standard) is the analytical standard of Hexadecanedioic acid (HY-W018161). This product is intended for research and analytical applications. Hexadecanedioic acid is an orally active metabolite produced by B. uniformis. Hexadecanedioic acid inhibits IRE1α-XBP1s-mediated flipogenesis and ferroptosis. Hexadecanedioic acid downregulates XBP1 and Hrd1 expression, activates the Nrf2/SLC7A11/GPX4 pathway. Hexadecanedioic acid can be used for the research of metabolic-associated fatty liver disease [1].
    Hexadecanedioic acid (Standard)
  • HY-RS14127

    Small Interfering RNA (siRNA) Others

    SYVN1 Human Pre-designed siRNA Set A contains three designed siRNAs for SYVN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SYVN1 Human Pre-designed siRNA Set A
    SYVN1 Human Pre-designed siRNA Set A
  • HY-RS18845

    Small Interfering RNA (siRNA) Others

    Syvn1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Syvn1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Syvn1 Mouse Pre-designed siRNA Set A
    Syvn1 Mouse Pre-designed siRNA Set A
  • HY-W018161S

    Isotope-Labeled Compounds IRE1 Ferroptosis Keap1-Nrf2 Glutathione Peroxidase Metabolic Disease
    Hexadecanedioic acid-d28 is the deuterium labeled Hexadecanedioic acid (HY-W018161). Hexadecanedioic acid (Thapsic acid) is an orally active metabolite produced by B. uniformis. Hexadecanedioic acid inhibits IRE1α-XBP1s-mediated flipogenesis and ferroptosis. Hexadecanedioic acid downregulates XBP1 and Hrd1 expression, activates the Nrf2/SLC7A11/GPX4 pathway. Hexadecanedioic acid can be used for the research of metabolic-associated fatty liver disease [1].
    Hexadecanedioic acid-d28
  • HY-B0124S3

    Isotope-Labeled Compounds Carbonic Anhydrase Apoptosis Neurological Disease
    Zonisamide- 15N,d4 is the 15N- and deuterium labeled Zonisamide (HY-B0124). Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy [1] .
    Zonisamide-15N,d4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: